June 28th 2022
Gynecologists and physicians, in concert with mothers, are key not only to a woman’s early awareness of both breast cancer and mammography but to awareness of breast cancer risk factors as well.
Aromatase inhibitor may improve outcome in premenopausal breast cancerJune 12th 2014
Adjuvant therapy combining ovarian suppression with an aromatase inhibitor-a class of drugs typically only recommended for postmenopausal patients-may be more beneficial for premenopausal patients with breast cancer than tamoxifen.
Black women at higher risk of triple-negative breast cancerMay 29th 2014
A new analysis of data from a nationwide hospital-based dataset shows that black women have higher odds of being diagnosed with triple-negative breast cancer-a subtype associated with poorer prognosis-than do white women, regardless of socioeconomic status (SES). The report was published in the June issue of Breast Cancer Research and Treatment.
25-year study questions value of screening mammographyFebruary 20th 2014
A new study with up to 25 years’ follow up is reopening debate about the value of screening mammography in women aged 40 to 59. Published in BMJ, the Canadian research found that 22% of women in that screening population-or 1 in every 424-had an over-diagnosed breast cancer.
Survival better with lumpectomy-not mastectomy-for early breast cancerJanuary 23rd 2014
According to a recent observational study in JAMA Surgery, women with early-stage invasive breast cancers have higher rates of disease-specific survival when they undergo breast-conserving therapy (BCT) than women who undergo mastectomy.
Walking lowers breast cancer riskOctober 10th 2013
Postmenopausal women who walk at least 7 hours per week have a significantly lower risk of breast cancer than their less active counterparts. Those are the findings of a large epidemiologic study published in Cancer: Epidemiology Biomarkers & Prevention.
Does HRT raise risk of breast cancer in thin or obese women?September 26th 2013
A new registry-based study sheds light on patient factors that may influence risk of breast cancer associated with use of postmenopausal hormone replacement therapy (HRT)-including race, weight, and breast density. Findings from the report, published in The Journal of the National Cancer Institute, suggest the greatest association between HRT use and breast cancer in women with low/normal body mass index (BMI) and extremely dense breasts.
USPSTF updates guidelines on medication for breast cancer risk reductionSeptember 26th 2013
In an update of its 2002 recommendation on use of medications for breast cancer risk reduction, the U.S. Preventive Services Task Force (USPSTF) is encouraging informed decision-making and cautioning against use of medications for prevention in women who are not at increased risk of the disease.
FDA prepares to approve Perjeta for use pre-surgerySeptember 19th 2013
The Food and Drug Administration’s (FDA) advisory committee cleared the way for the approval of pertuzumab (Perjeta) to treat patients before they have surgery to remove their HER2-positive tumors. If approved, pertuzumab would be the first neoadjuvant drug approval for any form of cancer. The drug was already approved by the FDA for treatment of late-stage breast cancer last year.
Women who don’t get mammograms most likely to die of breast cancerSeptember 19th 2013
A new multicenter analysis shows that most deaths from invasive breast cancer occur in women who don’t get routine mammograms. The findings, published in Cancer, point to a need to encourage routine screening in women younger than age 50.